- About Overview
- Diversity, Equity, and Inclusion
- Honors and Awards
- Facts and Figures
- Support the School
- Contact Us
- Organization Overview
- Dean’s Office
- Dean’s Office Overview
- PharmD Education Unit
- Office of Faculty Academic Affairs
- Office of Administration
- Pharmacy Practice Partnerships
- Department of Bioengineering and Therapeutic Sciences
- Department of Clinical Pharmacy
- Department of Pharmaceutical Chemistry
- Quantitative Biosciences Institute
- Org Chart
- Patient Care
Drilling down to the details of opioid signaling
Study sheds light on molecular basis of pain relief from opioid drugs
By Levi Gadye / Wed Jul 11, 2018
Antoine Koehl (Manglik lab)
Despite using opioids for centuries for pain management, we still don’t have a complete understanding of how drugs like morphine and oxycodone actually work. And that’s a problem for patients, who must weather side effects that can range from nausea and constipation to cognitive impairment, addiction, and, at high doses, even death.
When opioid drugs enter the bloodstream, they stimulate "µ-opioid receptors" on the surface of neurons in the brain. These receptors are part of a large class of proteins, called G-protein coupled receptors (GPCRs), which relay signals from outside and into the cell by stimulating partner molecules, called G-proteins, on the inside of the cell. Yet the details of how opiates produce their effects, wanted and unwanted, via GPCRs and G-proteins, have remained elusive.
Recent findings, led in part by Aashish Manglik, MD, PhD, have now revealed how the µ-opioid receptor engages with a particular G-protein as the first molecular step toward quelling pain. The researchers used a technique called cryo-electron microscopy, or cryo-EM, to directly observe an opioid drug activating the receptor, which then activates its G-protein. The study was published on June 13 in Nature.
Manglik is a faculty member in the UCSF School of Pharmacy’s Department of Pharmaceutical Chemistry, and he holds a joint appointment in the School of Medicine's Department of Anesthesia. He carried out this research as a graduate student and Distinguished Fellow at Stanford University.
“We’ve essentially captured this signaling event in the act,” Manglik explained to UCSF News. “These new atomic-level images will hopefully enable us to rationally design compounds that target different aspects of opioid signaling in the brain, with hopes of identifying new, safer painkillers.”
CryoEM Study Captures Opioid Signaling in the Act (UCSF News Center)
About the School: The UCSF School of Pharmacy aims to solve the most pressing health care problems and strives to ensure that each patient receives the safest, most effective treatments. Our discoveries seed the development of novel therapies, and our researchers consistently lead the nation in NIH funding. The School’s doctor of pharmacy (PharmD) degree program, with its unique emphasis on scientific thinking, prepares students to be critical thinkers and leaders in their field.